rushi21

Treatment options for wounds includes application of topical medication, sutures, staples, adhesives, compression therapy, hyperbaric oxygen therapy, biological dressings, and negative pressure wound therapy (NPWT).

Treatment options for wounds includes application of topical medication, sutures, staples, adhesives, compression therapy, hyperbaric oxygen therapy, biological dressings, and negative pressure wound therapy (NPWT). Negative pressure wound therapy, also called vacuum-assisted wound closure, has gained significant traction over the last decade as it is equally effective in acute and chronic wounds. NPWT is a relatively non-invasive wound therapy and offers various pips other conventional treatment options by facilitating better healing, shorter hospital stay, and fewer wound infections.

Get Exclusive Sample Report at: http://bit.ly/30lpsDC

Market Dynamics

The primary benefits of NPWT such as elimination of edema, providing a moist wound-healing environment, and stimulating angiogenesis and blood flow to the wound is increasing its uptake. Moreover, the new guidelines outlined by the World Health Organization (WHO) in November 2016, recommends use of NPWT in closed-surgical incision in order to reduce risk of surgical site infection. The guidelines also recommends use of portable NPWT devices. Furthermore, increasing prevalence of diabetes (422 million sufferers until 2014, WHO) and increasing number of medical surgeries (312.9 million in 2012, WHO) is expected to drive the market for NPWT globally.

Increasing prevalence of chronic wounds to fuel the demand in global negative pressure wound therapy devices market

According to the American Diabetes Association (ADA), diabetic foot ulcers costs the public and private payers in the U.S. US$ 9 billion – US$ 13 billion annually, in addition to diabetes treatment costs. Moreover, a study published by the ADA in 2014 found that the incidence of diabetic foot ulcers in the U.S. was 3.8% among the Medicare insured diabetic patients and 5.0% among privately insured diabetic patients. A study published in the Indian Journal of Health Sciences and Biomedical Research in 2015 revealed the prevalence of foot ulcers among diabetic patients in India to be 3%. With over 420 million diabetic patients globally (WHO, 2016), prevalence of 3% - 5% amounts to a sizeable population, highlighting the underlying potential of NPWT devices.

Moreover, with increasing age, prevalence of leg ulcers and other chronic wounds is also expected to increase. Although there is less prevalence of venous leg ulcer, treatment cost of this ulcer remains a burden on the economy. For instance, in U.K., prevalence of venous leg ulcers was 0.1%-0.3%, however, treatment costs was US$ 506 – US$ 760 million annually.

The treatment cost of chronic wounds can be reduced to a large extent by utilizing NPWT, as the frequency of change in dressings reduces and the device can serve for up to a month of therapy duration. This is expected to drive growth of the negative pressure wound therapy devices market over the forecast period.

Utilization of new technologies to improve clinical outcomes to favor the manufacturers in the global negative pressure wound therapy devices market

Connate Group plc, launched Avelle system, its first NPWT device, in August 2016. This device is based on a proprietary AQUACEL technology that prevents periwound maceration and is a canister-less disposable system with a 30 day usability period. Smith & Nephew plc, received the 2016 French Galien award for its PICO NPWT device. PICO being a single-use NPWT device, significantly reduces overall cost of treatment and the care needed for individual patients with chronic wound compared to conventional wound therapies (sutures, dressings, etc.). Such technologies with improved patient outcomes provides a competitive advantage to marketers of NPWT device and gain share in the global negative pressure wound therapy devices market.

Ask For Discount Before Purchasing This Business Report @ http://bit.ly/2Xv1IuV

Key companies covered as a part of this study include Smith & Nephew plc, Devon Medical, Paul Hartmann AG, Talley Group Limited, Coloplast A/S, ConvaTec Inc., Molnlycke Health Care AB, Medela AG, Kinetic Concepts, Inc., and Cardinal Health, Inc.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Most invasive surgical procedures often leave behind scars and vascular lesions. Aging results in loss of hair, wrinkles, and skin deterioration.

Until about a decade ago, skin diseases were not considered to be much of a concern among the medical fraternity, with focus mainly towards combating major diseases such as HIV/AIDS and hospital-acquired pneumonias. However, in primary care settings, skin disorders are the common diseases prevalent in tropical areas. HIV infection related skin diseases are especially common in sub-Saharan geographies. In 2015, according to Turkish Journal of Family Medicine & Primary Care, infections related to skin are common worldwide with a prevalence of pyoderma between 0.2% and 35%, for tinea capitis it is around 19.7%, for scabies it ranges between 0.2% and 24%, and for viral skin disorders it ranges between 0.4% and 9%.

Get Exclusive Sample Report at: http://bit.ly/2NCSLQE

Market Dynamics

Rise in number of skin infections and rise in demand for skin rejuvenation is expected to propel growth of the dermatology disease market. Rise in demand for skin rejuvenation therapy is backed up by increasing use of radiofrequency techniques, which in turn is expected to favor the market for dermatology devices market in the near future. Furthermore, high prevalence of skin mycoses globally is projected to have a positive effect on the growth for dermatology devices market. According to article published in 2008 by John Wiley & Sons, Inc., high prevalence of skin mycoses was around 20–25% and thus, was considered as one of the most prevalent forms of infection worldwide. The last decade has witnessed a spurt in incidence of skin diseases caused by pathogens such as anthropophilic and zoophilic dermatophytesm, which are especially prevalent in regions tropical regions due to the favorable growth environment. Also, change in lifestyle and awareness about the treatment is also one of the major factor affecting positively the growth of dermatology devices market. Scar and tattoo removal are some of the examples that require dermatology devices. According to Deccan Chronicles, in 2016, there were 25,000 tattoo removal cases recorded in India of the 128,218 cases worldwide, as revealed by a survey conducted by the International Society of Aesthetic Plastic Surgery (ISAPS) in 2015.

Advancement in technology is expected to be a threat for conventional treatment methods in the dermatology devices market

The treatment procedures that are minimally invasive are gaining attention in the medical community and among patients, worldwide. Therefore, there is a high demand for devices such as microdermabrasion, pens for pigmented lesions, scars, and loose skin, and laser therapy globally. The conventional surgical procedures used for the treatment of skin disorders are replaced with these devices, as conventional procedures leaves out unwanted scars post-surgery. Some of the safe and effective treatment options for acne scarring include laser resurfacing, dermabrasion, and chemical peels. Researches based on the effectiveness of laser and light therapies in treating mild to moderate acne is still going on.

Market Taxonomy

This report segments the global dermatology devices market on the basis of product type, application, end user, and geography. On the basis of product type, the market is categorized into microdermabrasion devices, lasers and others. The laser product type segment is sub-segmented into alexandrite laser, diode, fractional, infrared 1319 nm, nd:yag 1064 nm, potassium titanyl phosphate (ktp), pulsed. The application segment is divided into vascular lesions, scar removal, tattoo removal, hair removal, wrinkle removal, acne treatment, skin rejuvenation, pore reduction and others. The vascular lesions application segment is further divided into telangiectasia, hemangiomas, port wine stains and venous lakes and scar removal application segment is sub-divided into red or hypertrophic scars and hyper-pigmentation. For comprehensive understanding of market dynamics, the global dermatology market is analyzed across key geographical regions namely North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

PMD Beauty pioneered the at-home microdermabrasion device that allows users to perform microdermabrasion procedure at ease and convenient. The device has a large consumer base in the U.S., U.K. and Australia.

Ask For Discount Before Purchasing This Business Report @ http://bit.ly/2XLBGbd

This is expected to benefit the dermatology devices market players such as Valeant Pharmaceuticals International Inc., Lumenis, Ltd., Cynosure Inc., Syneron Candela Ltd., Avita Medical Ltd., Alma Lasers, Ltd., Lutronics Corporation, Beijing Toplaser Technology Co. Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., and Cutera, Inc.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Market Overview:

Wireless visual cortical stimulator devices are visual prosthetics used to restore functional vision of a blind user. It provides electrical stimulator that bypasses defected retinal cells and stimulates viable cells to induce visual perception. On October 26, 2016, Second Sight, announced its first implantation in a 30-year blind patient to provide human proof for the ongoing development of Orion I Visual Cortical Prosthesis (Orion I), wireless visual cortical stimulator. In 2013, the U.S. FDA approved Second Sight’s Argus II System, a visual cortical stimulator that provides electrical stimulation that bypasses defunct retinal cells to stimulate viable cells. The difference between Orion I and Argus II System is that Orion I uses wireless technology. The device allows restoring vision to patients completely blind due to glaucoma, cancer, diabetic retinopathy or trauma cases. The first implantation proved that the device perceive and localize individual light spots with no side effects associated with it. It is rare that all technological development offers string opportunity, though the first human test of Orion I, wireless visual cortical stimulator proved to be able to treat visually impaired patients with no side effects. The company expects to submit the application to the FDA in early 2017 for the initial completion of clinical trial of the complete system.

Get Exclusive Sample Report at: http://bit.ly/2xrq9io

Wireless visual cortical stimulator market is segmented on the basis of indication type and end users. On the basis of indication type, the market is segmented into cancer, diabetic retinopathy, trauma, glaucoma, and other indication. Diabetic retinopathy and glaucoma segments are expected to contribute major share to the overall market. ON the basis of end user, the visual cortical stimulator market is segmented into hospital, ambulatory surgical centers, emergency care units, specialized clinics, and others

Global Wireless Visual Cortical Stimulator Market Taxonomy

The global market is classified on the basis of following segments:

Indication Type:

Cancer

Diabetic Retinopathy

Trauma

Glaucoma

Others

End Users:

Hospital

Ambulatory Surgical Centers

Emergency Care Units

Specialized Clinics

Others

Increasing Incidence of Diabetic Retinopathy Provides Positive Future Outlook for Wireless Visual Cortical Stimulator Market

The global wireless visual cortical stimulator is expected to witness significant growth in the near future due to increasing number of diabetic retinopathy cases reported worldwide. It is the fifth-most common cause of preventable blindness and moderate to severe visual impairment. In 2010, an estimated 285 million people worldwide suffered from diabetes. The increasing trauma cases and cancer cases are expected to create lucrative growth opportunity for wireless visual cortical stimulator manufacturers and developers.

Request For Customization of Research Report @ http://bit.ly/2RVfZ31

The growing concern with blindness due to diabetes and governments or organizations initiatives to grow awareness among patients related to blindness treatment through campaigns and national diabetes awareness programs to act as a fuel to the growth of wireless visual cortical stimulator market. In October 2016, Kasturba Heath Society, Mahatma Gandhi Institute of Medical Sciences in India initiated diabetic care program to prevent blindness from diabetic retinopathy aimed to create awareness and prevent blindness from diabetic retinopathy. The CDC’s Vision Health Initiative (VHI) is one such initiative started by Center for Disease Control and Prevention aimed to create more effective network for vision loss prevention and eye health promotion. The presence of other alternative treatment methods like medication, visual cortical stimulator device will hamper the growth of wireless visual cortical stimulator. The time span for FDA approval and time required for adoption of device is expected to hamper the overall growth of wireless visual cortical stimulator industry. North America and Europe are expected to be major revenue contributors towards the market due to these regions being early adopters of novel technologies.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Pharmaceutical excipients are critical components of a pharmaceutical dosage form, ensuring drug safety and efficacy. Therefore, compatibility with API, adjacent excipients and dosage form are essential factors that need to be considered while selecting an excipient. Various types of excipients are used in a pharmaceutical formulations. This includes binders, diluents, glidents, disintegrants, emulsifiers, compressing agents, taste masking agents, lubricants, coating agents, sweeteners, and vehicles (base). Use of excipients is high in oral and topical dosage forms compared to parenteral. These excipients are extracted from different sources such as plant, animals, and minerals or are synthetically developed. The International Pharmaceutical Excipients Council (IPEC), formed in 1991, focuses on harmonizing manufacturing standards for pharmaceutical excipients globally.

Get Exclusive Sample Report at: http://bit.ly/2Xmlgqf

Market Dynamics

Demand for high-quality excipients is more in developed economies, while affordability is the key criteria considered for price sensitive emerging economies. China has emerged as the largest supplier of low-cost pharmaceutical API and excipients. India is the other fast emerging market to which production of excipients is outsourced owing to lower labor and production costs. North America and Europe lead the market for excipients as the number of excipient manufacturers are high in these regions. Moreover, high cost of manufactured excipients generates higher revenue for these regions compared to cost of material produced by manufacturers in Asia Pacific. However, growing pharmaceutical drug price pressure across the globe is expected to drive growth of the markets in China and India characterized by high supply of low cost excipients.

Oral And Topical Segment Is Driving The Pharmaceutical Excipients Market Growth

Excipients are largely used in the production of oral dosage forms such as tablets, capsules, and liquids when compared to parenteral dosage forms. The growth of excipients usage in oral dosage forms is expected to be 7.2% over the forecast period. Local players entering the pharmaceutical industry mark their entry with oral dosage forms, as manufacturing of these are easier when compared to other dosage forms. Economies such as India, Brazil, China, and U.S. are few major pharmaceutical excipients markets, as they have large presence of regional pharmaceutical players. Therefore, demand for excipients is expected to be high in such economies. Moreover, growing topical solutions (cream, gel, eye drops, skin patch) in dermatology and pain management categories is also expected to increase the demand for excipients, thereby driving growth of the market.

Patent Expiries To Provide Opportunities For Pharmaceutical Excipient Manufacturers

Symbicort (Budesonide/Formoterol Fumarate Dihydrate), Cialis (Tadalafi), Velcade (Bortezomib), Alimta (Pemetrexed), Vytorin (Ezetimibe and Simvastatin), Cubicin (Daptomycin), Reyataz (Atazanavir) and Sandostatin LAR (Octreotide Acetate) are some of the major blockbuster brands going off-patent in 2017. This will pave way for generic brands boosting the demand for respective pharmaceutical excipients. According to the McKinsey’s Global Generics report, nearly US$ 97 billion of drugs will go off-patent during 2017 – 2019.

In addition, advent of biosimilars would further propel growth of the pharmaceutical excipients market. Companies are investing in development of biosimilars to capitalize on this billion dollar market opportunity. However, strict regulatory hold over approval of biosimilars is slowing the approval of biosimilars being developed, in turn hampering growth of the pharmaceutical excipients market.

Inquire Here Before Purchase of Research Report @ http://bit.ly/2YsT15A

Growing demand for low cost medicines

Affordable healthcare is the primary objective of health regulators globally, something that is propagated by various such initiatives in place such as Obama Care Act and the actions of Drug Price Control Order (DPCO) in India. The DPCO has capped the prices of over 467 drugs to cater to unmet need of population with low income levels. According to the IMS Health 2015 data, average price of branded products has increased from US$ 71.91 in 2010 to US$ 91.92 in 2015. On the other hand, average price of generic products has declined from US$ 26.23 in 2010 to US$ 20.92 in 2015. Pricing pressure and high competition are major attributable factors to this decline. This has further contributed to wards the growth of pharmaceutical excipients market.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Pharmaceutical excipients are crucial contents of a formulation that enable effective drug absorption.

Wireless visual cortical stimulator devices are visual prosthetics used to restore functional vision of a blind user.

Most of the women worldwide are oblivious to the high risk of dreadful diseases such as cervical cancer, pelvic pain, uterine fibroids, and vaginitis that they are susceptible to. The Centers for Disease Control and Prevention (CDC) runs a National Breast and Cervical Cancer Early Detection Program (NBCCEDP) that has been running successfully for over 20 years. The program aims to create awareness and provide women in the low-income group or those who are uninsured, with regular breast and cervical cancer screening and diagnostic services. Early detection is vital in treating such diseases and such initiatives would propel growth of gynecological imaging devices market. Increasing prevalence of gynecological diseases would propel demand for gynecological surgical devices. The Obstetrics and Gynecology Devices Panel at the Food and Drug Administration (FDA) reviews and evaluates the safety and effectiveness of investigational and marketed gynecological devices to ensure patient safety.

Get Exclusive Sample Report at: http://bit.ly/2YoKxfL

Market Dynamics

Demand for gynecological devices would increase consequently with increasing gynecological surgeries. Although drugs are the first line treatment for a majority of gynecological diseases, surgeries are performed in severe conditions. Demand for such surgeries and consequently for devices used for the same are driven majorly by increasing incidence of gynecological diseases such as cervical cancer, uterine fibroids, endometriosis, vaginitis and pelvic inflammatory disease (PID). PID is the second most common and serious complications among the women in the U.S. According to the Endometriosis UK, 10% of the population of women worldwide is affected by endometriosis (2016). Global female population in the age group of 15-64 years increased from 63% in 2010 to 65.6% in 2015 (World Bank). This age group is highly prone to gynecological problems, owing to changing lifestyle and growing infection rates. Risk of gynecological problems increases with age. Female population aged 65 years and above increased exponentially from 6.8% in 2010 to 8.2% in 2015 (World Bank). Need for gynecological devices is expected to increase considerably with this growing aging population. This trend would further propel growth of the gynecological devices market.

Growing gynecological procedures and disorders

According to the Endometriosis UK, 10% of the population of women worldwide is affected by endometriosis (2016). Moreover, pelvic inflammatory disease (PID) is the second most common and serious complications among the women in the U.S. Aging further increases the risk of cervical cancer, uterine fibroids, and vaginitis. Surgeries are essential in complex gynecological indications. Being critical and complex surgical procedures, demand for advance gynecological devices would increase during the forecast period. This would propel the growth of gynecological devices market.

Patient safety is the major point of care for device manufacturers

Certain gynecological devices such as intra-uterine device (IUD), morcellators, and vaginal speculums can cause infection and skin rashes. Several cases of skin rashes and pelvic pain were reported among women in the U.S. until 2016, who used Essure IUD. The U.S. FDA therefore asked the manufacturer Bayer, to include a black box warning on the product pack. Considering their highly personal application areas, any adverse effects associated with the devices would severely dent growth prospects of the gynecological devices market. Advent of robotic surgery is expected to lead to further innovations in gynecological devices in future. Companies therefore, need to work closely with surgeons, in order to provide innovative solutions catering to their specific demands.

Highly populous emerging economies to be major target markets

Emerging economies such as India and China are home to over 80% of the global population (European Central Bank). A large population inadvertently creates a proportionally large patient pool. Manufacturers of gynecological devices can potentially target these emerging nations in Asia, Latin America, Africa and Middle East region for business expansion. Use of contraceptives is projected to increase in emerging nations with increasing awareness among the population and initiatives by various governments to encourage family planning. The Centers for Disease Control and Prevention (CDC) runs a National Breast and Cervical Cancer Early Detection Program (NBCCEDP) to create awareness and provide women in the low-income group or those who are uninsured, with regular breast and cervical cancer screening and diagnostic services. Growing awareness initiatives for women population is creating a demand for early diagnosis of a disease. Improving healthcare infrastructure would be an effective driver for gynecological devices market growth. A study published in the Journal of Mid-Life Health in 2014 concluded that nearly 90% of surgeries in rural India were conducted without histopathological diagnosis. However, healthcare investment in India is increasing which is expected to establish more hospitals and surgical centers thus, driving growth of the gynecological devices market.

Inquire Here Before Purchase of Research Report @ http://bit.ly/2FMiboN

Key companies covered as a part of this study include Ethicon, Inc., Hologic, Inc., Stryker Corporation, Cooper Surgical, Inc., Karl Storz GmbH& Co. KG, Boston Scientific Corporation, and Richard Wolf GmbH.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Cytomegalovirus (CMV) is a virus that belongs to herpes virus family that remain dormant in the human body. CMV infection can occur in people of all ages worldwide. CMV is a communicable disease that spreads through body fluids such as saliva, blood, urine, semen, and breast milk. Presence of CMV infection can be detected by various testing methods based on which the global cytomegalovirus infection treatment and diagnosis market can be analyzed:

Serologic test

Polymerase chain reaction (PCR) test

CMV diagnosis is very critical in pregnant women and immunocompromised individuals. Enzyme-linked immunoassay test is the most widely used serologic testing for CMV infection in laboratories. Besides, PCR technique is also widely implemented for samples of saliva, and urine. Awareness about the infection is essential as most of the cases go undiagnosed at early stages as the disease is asymptomatic.

Download PDF Brochure Of This Research Report @ http://bit.ly/2YpdUyK

Cytomegalovirus Infection Market: Treatment Approach

People diagnosed with high risk of CMV infection may be given anti-viral medications to prevent the disease to get in to active stage. There is no cure available for treating the CMV infection. Ganciclovir, Val ganciclovir, Cidofovir, Valacyclovir and Foscarnet are few major anti-viral medications prescribed. In some cases, CMV immune globulin contains antibodies (proteins) may be prescribed to prevent CMV infection. There are certain products in pipeline which includes Cytovir CMV, Letermovir, CytoTect CP 70, Brincidofovir and ASP0113, commercialization of which is expected to fuel the global CMV infection treatment and diagnosis market growth in the near future.

Vital Statistics For The Global Cytomegalovirus Infection Treatment And Diagnosis Market

Besides, diagnosis of new CMV cases would be a propelling factor for global cytomegalovirus infection treatment and diagnosis market. The Public Health Agency of Canada estimates that 40%-100% of the global population have CMV antibody present in their body. Immunocompromised patients (HIV, organ transplant), premature infants, newborns and with congenital CMV are at high risk of developing serious illness with CMV infection.

According to the Centers for Disease Control and Prevention (CDC), one in every 150 infants are born with congenital cytomegalovirus (CMV) infection in the U.S. However, only one in five infants infected with CMV have long term health problems. Prevailing infection rates and demand for effective treatment therapies would be thrusting the cytomegalovirus infection treatment and diagnosis market growth.

Cmv Infection Treatment And Diagnosis Market: Regional Overview

Early diagnosis practices would drive the global cytomegalovirus infection treatment and diagnosis market in developed regions such as North America and Europe, where accessibility to advanced diagnostic and treatment facilities is high compared to the emerging economies. For market players in the diagnosis and treatment of CMV infection, ensuring accessibility and healthcare investment in emerging nations would be critical to generate better return on investments.

Ask For Discount Before Purchasing This Business Report @ http://bit.ly/2KPnfg9

Some of the major players in the global cytomegalovirus infection treatment and diagnosis market are Merck & Co. Inc., Cell Medical Ltd., Chimerix, Inc., Affymetrix, Inc., Abbott Laboratories, Inc., Becton, Dickinson and Company, Johnson & Johnson, Bio-Rad Laboratories, Inc., and F. Hoffmann-La Roche Ltd.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Most of the women worldwide are oblivious to the high risk of dreadful diseases such as cervical cancer, pelvic pain, uterine fibroids, and vaginitis that they are susceptible to

Cytomegalovirus (CMV) is a virus that belongs to herpes virus family that dormant in the human body.

Antibody drug conjugate is a significant class of highly potent bio drugs envisioned as a broad therapy for treatment of cancer

Antibody drug conjugate is a significant class of highly potent bio drugs envisioned as a broad therapy for treatment of cancer. Unlike chemotherapy, antibody drug conjugate are proposed to mark and kill only cancer cells. Antibody drug conjugates are compound molecules that comprise antibodies linked to a biologically active cytotoxic drug.

Get Exclusive Sample Report at: http://bit.ly/2RPnqbV

By uniting the exclusive targeting capacities of mAB with anti-cancer drugs, ADCs allow for subtle judgment between healthy and diseased tissue. This entails that the antibody drug conjugates kill only cancer cells and ensure that other dynamic cells are less severely affected. This exceptional phenomenon of killing only cancer cells increase the importance of use of ADCs, which would indirectly boost growth of the global antibody drug conjugates market.

Commercialization of 7-10 ADCs in the following decade, would lead to revenue to surge to over US$ 10 billion over the forecast period of market

In terms of marketing, three antibody drug conjugates have received regulatory approval. The U.S. FDA approved one of the ADC in 2001 manufactured and developed by Pfizer/Wyeth, to treat acute myelogenous leukemia. The drug was subsequently withdrawn in June 2010, leaving only two antibody drug conjugates in the market. The two drugs marketed for ADCs are Brentuximab vedotin and Trastuzumab emtansine, developed and manufactured by Seattle Genetics and Millennium/Takeda and Genentech and Roche, respectively. Around 45 antibody drug conjugates molecules are under clinical trials, with the preclinical pipeline expanding at a high rate. Of all the 45 molecules, around 25% are under Phase II or Phase III of development. Frequently used cytotoxins for antibody drug conjugates under trials include auristatin, calicheamicin, maytansine and duocarmycin. Auristatin is the dominant compound accounting for over 50% of antibody drug conjugates in clinical development. Roche has 10 compounds under clinical trials, and this is the most developed pipeline of antibody drug conjugates. Globally, 70%-80% of antibody drug conjugates manufacturing is currently outsourced. There are limited number of contract manufacturers that have high-end manufacturing equipment for development of cytotoxins.

Antibody drug conjugates market is still in its infancy, with two approved ADCs to propel the market to two digit billion dollar mark by 2020

The global antibody drug conjugates market is segmented on the basis of drug and geography. On the basis of drug, the market is divided into Adcetris and Kadcyla.

Major pharmaceutical company opt for contract manufacturer for development and manufacture of antibody drug conjugates

Regional segmentation of the antibody drug conjugates market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. Europe accounts for the largest share in the global market mainly due to presence of many contract manufacturing companies with advanced manufacturing equipment. Lonza is one of the top contract manufacturing companies in Europe, which has operations across France and Germany, with its headquarters in Switzerland. One of the facilities operated by the company is a deck to chemical manufacturing capabilities and develop peptides, small molecule active pharmaceutical ingredients, highly potent active pharmaceutical ingredients, cytotoxics agents, antibody drug conjugates, and microbial products. The company also offer proficiency in chemical, pharmaceutical, agrochemical and food industries by providing clients with yields such as high-class active substances, organic chemicals and intermediates.

Request For Customization of Research Report @ http://bit.ly/2FJ0bLT

Large number of clinical trial molecules in pipeline to boost growth of antibody drug conjugates market

Key players operating the antibody drug conjugates market include Hoffmann-La Roche Ltd, Seattle Genetics, Takeda, ImmunoGen Inc, Pfizer Inc., Sanofi, AbbVie Inc, Cellldex Therapeutics, Synthon, and Progenics Pharmaceuticals. Major companies in the antibody drug conjugates industry are constantly working on research and development, as the market is largely untapped and offer highly lucrative growth opportunities. For instance, there are only two antibody drug conjugates available worldwide that are used to treat cancer, and there are over 40 molecules under clinical trials. Considering the alarmingly high incidence rate of cancer across the globe, the antibody conjugates market is expected to ride on a wave of positive growth in the foreseeable future.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. Shah

Coherent Market Insights

1001 4th Ave, #3200

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

In vitro diagnostics are diagnostic devices and equipment that extract vital information about an individual or patient after a sequence of tests. Introduction of novel diagnostics test applications on the backdrop of advancements and innovations in the IVD technologies by various organizations has resulted in rampant growth of the in vitro diagnostics (IVD) market, which is expected to sustain in the near future. Diagnoses and tests are precursors to any treatment, which makes in vitro diagnostic market highly lucrative. However, majority of the tests are remotely performed making their presence and use unnoticed. Furthermore, increasing elderly population base and rising demand for diagnostic testing is projected to spur growth of the in vitro diagnostics (IVD) market over the forecast period (2016–2024). Also, growing prevalence of diabetes has increased the demand for in vitro diagnostic tests in the recent past, which is further expected to add on to the sales revenue of the in vitro diagnostic market. In 2014, as per National Diabetes Statistics Report 2014, around 9.3% of the population in the U.S. suffered from diabetes and around 28.0% were undiagnosed.